Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
68Ga-HER2
- Development stage
- Unknown
- Lead developer
- Affibody
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Peptides
- Administration
- Intravenous
01
Overview
68Ga-HER2 refers to a class of gallium-68 labeled radiopharmaceutical imaging agents designed for positron emission tomography (PET) imaging of human epidermal growth factor receptor 2 (HER2) expression in solid tumors. These agents typically consist of a HER2-targeting moiety—such as an affibody (e.g., ABY-025, NOTA-MAL-MZHER2), a nanobody (e.g., VHH1), or a monoclonal antibody (e.g., trastuzumab)—conjugated to a chelator (such as DOTA or NOTA) and radiolabeled with the positron-emitting isotope gallium-68 (68Ga). By binding specifically to HER2 receptors on tumor cells, 68Ga-HER2 PET/CT or PET/MRI allows for noninvasive, whole-body visualization and quantification of HER2 expression. This molecular imaging approach is used to assess HER2 heterogeneity, select patients for HER2-targeted therapies, and monitor early therapeutic response or predict pathological complete response (pCR) to neoadjuvant therapy in patients with HER2-positive breast or gastric cancers.
- Other names
- 68Ga-HER2 affibody68Ga-HER2 nanobody68Ga-HER2 PET/CTGa-68 HER2Ga68 HER2Ga 68 HER2gallium Ga 68-HER2
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on 68Ga-HER2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 68Ga-HER2.